Introduction
Acute promyelocytic leukemia (APL) is characterized at cellular level by the accumulation of blasts blocked at the promyelocytic stage of cell differentiation (reviewed in Refs 1 and 2). At the molecular level APL is characterized by a specific chromosomal translocation involving chromosomes 15 and 17 [t(15;17) ]. [3] [4] [5] [6] As a consequence of this translocation a chimeric gene is formed encoding for the fusion protein PML/RAR␣. [7] [8] [9] [10] RAR␣ encodes one of the retinoic acid receptors; 11, 12 PML encodes a protein of unknown function localized in subnuclear structures called nuclear bodies (NB) or PML oncogenic domains (POD). [13] [14] [15] [16] [17] [18] A major challenge in elucidating the pathogenesis of APL consists in the understanding of the molecular mechanisms through which the PML/RAR␣ protein mediates the differentiation block. In this context, we have initially shown that the PML/RAR␣ protein can efficiently block Vitamin D 3 -induced differentiation of promonocytic U-937 cells and increases the survival and proliferation of cells grown in low serum concentrations. 19 Furthermore, retinoic acid restores the differentiative response to Vitamin D 3 . 20 Subsequently, we have shown that PML/RAR␣ overexpression in human erythroleukeCorrespondence: U Testa, Department of Hematology and Oncology, Istituto Superiore di Sanità, 00161, Rome, Italy; Fax: 39 649387087 Received 31 July 1997; accepted 8 December 1997 mia K562 cells leads to an inhibition of hemin-induced erythroid differentiation. 21 Finally, we observed that PML/RAR␣ expression in growth factor-dependent human erythroleukemia TF-1 cells elicited a marked decrease of apoptosis induced by growth-factor deprivation. 22 These biological effects of PML/RAR␣ protein seem to be responsible for the crucial features of the APL phenotype, ie the accumulation of hematopoietic precursors blocked at the promyelocytic stage of differentiation.
A crucial question is whether PML/RAR␣ differentiation block occurs only at the promyelocytic stage or may also operate in different cell lineages and at various differentiation stages. The 15;17 translocation may occur at the level of myeloblasts/promyelocytes or of committed progenitors or of an earlier progenitor cell allowing differentiation towards the granulocytic lineage until the promyelocytic stage. In this context, studies carried out on a few APL patients have shown that CD34
− hemopoietic progenitor cells, synthesize PML/RAR␣ transcripts. 23 At the molecular level PML/RAR␣ may block specifically granulocytic differentiation or, alternatively, may affect differentiation master genes.
To gain insight into these issues we have explored the effects of PML/RAR␣ on differentiation programs distinct from those triggered by Vitamin D 3 (monocytic differentiation) or hemin (erythroid differentiation); thus, the fusion protein was expressed in the TF-1 cell line, which consists of hematopoietic precursor cells. We have explored the differentiation properties of the TF-1 precursor cell line and showed that these cells can be forced to terminal megakaryocytic maturation by phorbol esters and thrombopoietin (Tpo). In these cells PML-RAR␣ expression is able to inhibit the megakaryocytic differentiation pathway, similarly to the monocytic and erythroid pathways.
Materials and methods

Expression of PML/RAR␣ cDNA in TF-1 cells
The MT-PML/RAR␣ expression vector has been previously described. 19 The MT-PML/RAR␣ 24 and the expression vector alone (MT-1 plasmid) were electroporated into TF-1 cells according to established procedures. 25 Two days after transfection the medium was changed to selective medium and cells G418-resistant selected under limiting dilution conditions.
Western blotting analysis
Western blotting analysis of cell lysates was performed as described 9 using an anti-human RAR␣ rabbit polyclonal antibody (PPa(F)) directed against the F domain of the RAR␣ protein (gift from P Chambon, Institut de Génétique et de Biologie 
Phenotypic analysis
Monoclonal antibodies:
The following mAbs were used to assess the maturation level of TF-1 cells: (1) Surface markers immunofluorescence analysis:
The erythroid, megakaryocytic, monocytic and granulocytic maturation of TF-1 clones was determined by the percentage of cells reacting with specific mAbs, as assessed by FACS. This analysis also allowed evaluation of antigen expression level by fluorescence-labeling intensity. Thus, cells were incubated for 60 min at 4°C in the presence of an appropriate mAb dilution. Each antibody was conjugated with either fluorescein isothyocianate (FITC) or phycoerythrin (PE). After three washes with cold PBS (HyClone, Cramlington, UK), cells were resuspended in PBS containing 2.5% formaldehyde, and then analyzed by FACS for fluorescence intensity. At least 4000 cells were analyzed for each determination. Polyclonal mouse immunoglobulins (Becton Dickinson) of the same isotype as the specific mAb were used as negative controls for the immunofluorescence reaction.
Cell cultures:
The wild-type TF-1 cell line 26 as well as transfected mutants were maintained in RPMI 1640 medium (Hyclone) and 10% FCS (Hyclone), supplemented with 10 ng/ml recombinant human GM-CSF (Sandoz, Basel, Switzerland).
1␣ 25OH-VitD 3 and 9cis-retinoic acid (9cis-RA) were generously provided by Roche (Basel, Switzerland). Phorbol-dibutyrate, all trans-RA (ATRA) and dimethylsulfoxide (DMSO) were purchased from Sigma (St Louis, MO, USA). Recombinant human Tpo was generously provided by Genentech (San Francisco, CA, USA).
For induction of cell differentiation TF-1 wild-type or PML/RAR␣ transfectants were diluted with fresh medium at 50 000 cells/ml and an aliquot of cells was first incubated for 8 h with 80 M ZnSO 4 and 300 g/ml human apotransferrin (Sigma) prior to the addition of chemical inducers. 
Growth factor receptor expression
The expression of IL-3 receptor (IL-3R), c-kit and c-mpl was analyzed by flow cytometry using specific mAbs: PE-labeled anti-IL-3R mAb, clone 9F5 which interacts with IL-3R␣ chain (PharMingen, San Diego, CA, USA); PE-labeled anti-human ckit (Immunotech, Marseille, France); purified anti-human cmpl (Genzyme, Cambridge, MA, USA). For IL-3R and c-kit expression the cells were incubated for 60 min at 4°C and then analyzed for red fluorescence. For c-mpl expression TF-1 cells were first incubated for 60 min at 4°C in the presence of 5 g/ml of this antibody, washed with cold PBS and then incubated for 30 min at 4°C with biotin-conjugated sheep anti-mouse IgGs (Cappel laboratories, Westchester, PA, USA); after washing with cold PBS, cells were incubated with PE-labeled streptavidin (Dakopatt) and then analyzed by flow cytometry.
RT-PCR analysis
Total RNA from 1 × 10 5 cells was extracted by CsCl gradient technique and reverse transcribed according to the manufacturer's instruction (Boehringer, Mannheim, Germany). PCR was performed in a final volume of 50 l in the presence of 2.5 U of Taq polymerase (Perkin-Elmer Cetus, Norwalk, CT, USA). The samples were amplified for EpoR, Mpl, GpllIa, PF4 and NF-E2 using the following primers and probes at the indicated annealing temperature for 30 cycles.
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Figure 1
Morphological features of wild-type TF-1 cells and two PR clones grown for 4 days in the absence of inducers (control) or in the presence of PDB + Tpo or Zn + PDB + Tpo. Cells are cytospun on glass slides and stained with May-Grü nwald. Undifferentiated TF-1 cells routinely grown in the presence of GM-CSF display membrane markers of early hemopoietic progenitor cells (ie they are almost entirely CD34 and CD33 positive) and coexpress both erythroid (glycophorin A) and MK membrane markers (CD41, CD42a, CD61 and CD62) ( Table 1) .
In a first set of experiments we have evaluated the capacity of TF-1 erythroleukemic cells to undergo MK differentiation using a PKC inducer (PDB) or the specific MK HGF Tpo added alone or in combination. Incubation of TF-1 cells with Tpo alone did not modify the level of expression of erythroid and MK membrane markers (Table 1) . Furthermore, Tpo alone did not sustain the growth of TF-1 cells (data not shown).
Addition of PDB to TF-1 cells induces adherence to the plastic surface and growth arrest, associated with inhibition of erythroid marker expression (glycophorin A) and increase of MK membrane markers (CD41, CD42a, CD61 and CD62) ( Table 1) . No monocytic membrane markers (ie CD14) are detectable following PDB addition ( Table 1 ). The simultaneous addition of both PDB and Tpo further enhanced the induction of MK membrane markers, as compared to the levels observed in cells treated with PDB alone (Table 1) .
Morphological analysis of TF-1 cells showed that (see Parallel studies carried out by RT-PCR mRNA analysis showed that (see Figure 2 ): (1) undifferentiated TF-1 cells express GpIIIa, as well as NF-E2 mRNA but only low levels of mRNA encoding mpl; furthermore, they possess EpoR mRNA; (2) Tpo-treated TF-1 cells exhibited the induction of TpoR; (3) PDB-treated TF-1 cells displayed a slight induction of mpl and GpIIIa mRNA and relevant induction of PF4 mRNA; and (4) TF-1 cells grown in the presence of PDB + Tpo showed a marked increase of mpl, Gpllla, PF4 mRNA levels, associated with a marked decline of EpoR mRNA level.
Effects of PML/RAR␣ expression on MK differentiation of TF-1 cells PML/RAR␣ cDNA was expressed in TF-1 cells by electroporation of a plasmid containing the PML/RAR␣ cDNA under the control of the Zn 2+ -inducible MT1 promoter. Cells were selected in G418 and subcloned by limiting dilution. PML/RAR␣ protein expression levels were assessed by Western blot using a specific antibody directed against the RAR␣ F region 9 ( Figure 3 ). Two clones that overexpressed PML/RAR␣ (MTPR1A and MTPR2A) were selected for further analysis.
Both PML/RAR␣-uninduced TF-1 clones displayed a cell morphology and a membrane phenotypic pattern comparable to that observed for wild-type TF-1 cells (Figures 4 and 5) . These clones induced in the absence of Zn 2+ by PDB + Tpo exhibited a morphologic and phenotypic megakaryocytic maturation, comparable to that observed for wild-type TF-1 cells (Figures 1, 4 and 5) . However, in the presence of Zn
2+
Figure 3
RT-PCR analysis of mRNA encoding EpoR, c-mpl, Gpllla, PF4 and NF-E2 in wild-type TF-1 cells grown in the absence of inducers or in the presence of PDB, Tpo or PDB + Tpo.
Figure 4
Expression of membrane differentiation antigens CD34, CD33 and glycophorin-A in wild-type TF1 cells, and two PR clones grown in the absence of inducers (control) and in the presence of either PDB + Tpo or Zn + PDB + Tpo. Data represent mean ± s.e.m. observed in three separate experiments.
TF-1 PML/RAR␣ induced with PDB + Tpo showed a marked inhibition of their capacity to differentiate to megakaryocytic cells. Particularly, cell morphology of PML/RAR␣ clones grown in the presence of Zn 2+ and PDB + Tpo displayed only a partial megakaryocytic differentiation, as indicated by the absence of large cells, by the virtual absence of cells showing two, four or more nuclei per cell and by the presence of a basophilic cytoplasm with no granulations (Figure 1) .
Importantly, wild-type TF-1 cells treated with Zn 2+ and PDB + Tpo showed a level of megakaryocytic maturation comparable to that observed in the same cells grown in the presence of PDB + Tpo, thus indicating that the inhibitory effect on megakaryocytic differentiation elicited by Zn 2+ in PML/RAR␣ clones is related to the expression of transfected genes and not to an inhibitory activity of Zn 2+ on megakaryocytic differentiation.
Evaluation of the effect of PML/RAR␣ on growth factor receptor expression in TF-1 cells Previous studies have shown that PML/RAR␣ expressing TF-1 cells are resistant to apoptosis induced by growth factor deprivation; 22 in addition, resistance to the effect of Tpo could be determined by a down-regulation of its receptor. Therefore, here we have investigated the effect of PML/RAR␣ on growth factor receptor expression. Interestingly, induction of PML/RAR␣ expression in these cells was associated with a significant up-modulation of three hematopoietic growth factor receptors (IL-3R, c-kit and c-mpl), all involved in the control of hematopoietic cell proliferation ( Figure 6 ). The levels of IL-3R, c-kit and c-mpl expression observed in TF-1 PML/RAR␣ + clones before Zn 2+ addition are comparable to those observed in wild-type TF-1 cells, while after Zn 2+ addition, which induces PML/RAR␣ synthesis, they are significantly higher than those observed in wild-type TF-1 cells (Figure 6 and data not shown). The increased expression of these growth factor receptors may contribute to increased resistance of TF-1 cells to apoptosis.
Following induction of TF-1 cells with PDB + Tpo c-kit expression is down-modulated, while c-mpl and IL-3R
Figure 6
Flow cytometric analysis of IL-3R, c-kit and c-mpl expression in a TF-1 PR clone grown in the absence of additives (control), or with Zn addition or in the presence of PDB + Tpo or Zn + PDB + Tpo. One representative experiment is shown. expression are up-modulated ( Figure 6 ). These observations are in line with the corresponding pattern of expression of these receptors observed during normal human megakaryopoiesis. 29 
Discussion
Previous studies 26, 28 assessed, on the basis of morphologic or phenotypic criteria, that TF-1 cells induced with a phorbol ester undergo monocytic/macrophagic differentiation. We show in the present study that, under appropriate conditions, PDB causes MK differentiation of TF-1 cells. This conclusion is in line with the observation that the majority of human erythroleukemic cell lines isolated from patients with either acute or chronic leukemias exhibit the capacity to differentiate in vitro along both the erythroid and megakaryocytic lineages. [30] [31] [32] This property reflects the existence of a common erythroid and megakaryocytic progenitor. 33, 34 Previous studies have shown that UT-7, a growth factordependent cell line established from a patient with acute megakaryoblastic leukemia, 35 represents a useful in vitro model to study megakaryocytopoiesis. [36] [37] [38] [39] [40] Particularly, UT-7 TPO and UT-7 GM 38 sublines undergo megakaryocytic differentiation following incubation with Tpo. UT-7 cells have many similarities with TF-1 cells.
Optimal megakaryocytic differentiation of TF-1 cells was obtained by the combination of a phorbol ester (PDB) and Tpo, the cytokine regulating megakaryocytic differentiation and maturation. 41 Previous studies carried out on a variety of either erythroleukemic or megakaryocytic lines have shown that PKC activators (phorbol esters) are inducers of megakaryocytic differentiation. [30] [31] [32] The capacity of TF-1 cells to be stimulated to differentiate by Tpo is not surprising in that these cells possess low, but significant levels of TpoR, 42 whose expression is greatly potentiated by Tpo and by PDB + Tpo (present study). This observation is in line with a recent study showing that Tpo markedly stimulates the expression of its membrane receptor in highly purified human hemopoietic progenitor cells. 29 However, it must be underlined that TF-1 cells cannot differentiate to mature megakaryocytic cells when grown with Tpo alone but only when Tpo is added together with PDB. In this context, the precise role of Tpo consists in potentiating the stimulatory effect of PDB which is required to bypass the leukemic differentiation block and thus to induce megakaryocytic differentiation.
PML/RAR␣ expression in TF-1 cells induces a marked inhibition of the megakaryocytic differentiative potential triggered by PDB plus Tpo. This observation, together with previous studies, [19] [20] [21] suggests that PML/RAR␣ overexpression possesses a wide capacity to interfere with different hematopoietic programs, including monocytic, 19 ,20 erythroid 21 and megakaryocytic (the present study). These observations suggest that PML/RAR␣ may act on master differentiation genes that are involved in the process of hematopoietic differentiation/maturation.
The inhibitory effect of PML/RAR␣ on megakaryocytic differentiation is a phenomenon involving the coordinated reduction of CD41, CD42a, CD42b, CD61 and CD62 antigen expression and polyploidy. This observation suggests that PML/RAR␣ interferes with factors that regulate the entire cellular differentiation program and does not simply regulate the expression of a few markers.
Since PML/RAR␣ appears to interfere with the basic regulation of cell differentiation, we have studied the expression of known transcription factors that were shown to participate in the control of the early stages of hematopoietic differentiation. In this context, an inhibitory effect of PML/RAR␣ on the expression of NF-E2 and GATA-1, two transcription factors involved in the control of megakaryopoiesis 43, 44 can be ruled out; in fact, overexpression of PML/RAR␣ did not modify the level of NF-E2 and GATA-1, both transcription factors being highly expressed both in uninduced and PDB plus Tpo-treated TF-1 cells (data not shown).
The mechanism(s) through which PML/RAR␣ inhibits hematopoietic differentiation remain largely unknown. However, the fact that the fusion protein blocks differentiation along virtually all hematopoietic lineages (granulocytic, monocytic, erythroid and megakaryocytic) implies major interference with key molecular events involving either differentiation of pluripotent stem cells into committed hemopoietic progenitors or of the different committed progenitors into the respective precursors. Experiments involving enforced expression of PML/RAR␣ into pluripotent hematopoietic progenitors would clarify this point. In this context, it is important to underline that the maturation block is a prominent feature of APL and ATRA, and although induces differentiation of APL blasts from promyelocytes to neutrophils, is unable to induce a complete morphological maturation of APL cells as shown by secondary-granule deficiency, a hallmark of abberantly differentiated leukemic cells. 45 Finally, we also observed that PML/RAR␣ expression in TF-1 cells markedly stimulates IL-3R, c-kit and c-mpl expression. This finding rules out the hypothesis that low Tpo response might be due to receptor down-regulation. All three receptors mediate hematopoietic cell proliferation/ differentiation (discussed in Ref. 29) . This phenomenon may be relevant for the understanding of the mechanism which render APL cells more resistant to apoptosis than their normal counterparts. 19 In line with this interpretation, recent studies indicate that IL-3R␣ chain overexpression in cytokine-dependent FDCP-1 cell line allowed the cells either to proliferate in suboptimal concentration of IL-3 or to became growth factor-independent. 46 In this context, it is of interest that in a previous study we showed that PML/RAR␣ expressing TF-1 cells are more resistant to apoptosis induced by growth factor deprivation than wild-type TF-1 cells. 25 The increased expression of growth factor receptors observed in PML/RAR␣ + TF-1 cells may partially explain their increased resistance toward apoptosis induced by growth factor starvation. Furthermore, in a previous study carried out by Dubois et al 47 on 16 APL patients it was shown that patients whose blasts secrete CSF, GM-CSF or IL-3 did not achieve complete remission following induction therapy with ATRA.
In conclusion, the present study provides evidence that: (1) TF-1 erythroleukemic cells possess the capacity to undergo terminal megakaryocytic differentiation when grown with PDB + Tpo; and (2) overexpression of PML/RAR␣ in these cells leads to a marked inhibition of the megakaryocytic differentiation program.
